Talimogene Laherparepvec
Amgen
['melanoma']
neoadjuvant treatment with the oncolytic virus t-vec continued to demonstrate consistent improvements in efficacy at 5 years compared with surgery alone for patients with stage iiib to ivm1a melanoma, according to data presented at #esmo22 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.